Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Pituitary[TA]) articles in PubMed
1,052 results
  • Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. [Journal Article]
  • Pituitary 2016 Sep 8P
  • Tritos NA, Biller BM
  • CONCLUSIONS: Pegvisomant is an effective therapeutic agent in patients with acromegaly who are not in remission after undergoing pituitary surgery. It mitigates excess GH action, as demonstrated by IGF-1 normalization, but has no direct effects on pituitary tumors causing acromegaly. Regular surveillance for possible tumor growth and adverse effects (hepatotoxicity, skin manifestations) is warranted.
  • Complications of acromegaly: thyroid and colon. [Review]
  • Pituitary 2016 Sep 8P
  • Tirosh A, Shimon I
  • CONCLUSIONS: Thyroid micro-carcinomas are probably over-diagnosed among acromegalic patients. In regard to colon cancer, there is no sufficient data to suggest that colon cancer risk is higher in acromegaly compared to the general population.
  • Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels. [Journal Article]
  • Pituitary 2016 Sep 6P
  • Livshits A, Kravarusic J, … Molitch ME
  • CONCLUSIONS: Small, intrasellar microadenomas may be associated with elevated PRL levels due to possible direct hormone production [prolactinoma] or possibly to interference with portal vessel blood flow. In monitoring hyperprolactinemic MEN1 patients for the development of pituitary adenomas, measurement of PRL levels is insufficient and periodic MRI scans are necessary at a more frequent interval than every 3-5 years. This may also pertain to patients with "idiopathic" hyperprolactinemia.
New Search Next